secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001628280-24-045456
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus Q3 revenue up 18.4% to $378.7M; adjusted EPS $1.70 beats prior year
----------------------------------------------------------------------------

- GAAP net income $131.1M ($1.79 diluted EPS) vs $132.0M ($1.88) in Q3 2023.
- PYLARIFY sales $259.8M (+20.6%); DEFINITY sales $77.0M (+14.3%).
- Acquired NAV-4694, a Phase 3 beta-amyloid imaging agent; NDA planned for 2026.
- CMS CY2025 final rule improves separate payment for diagnostic radiopharmaceuticals including PYLARIFY, effective Jan 1, 2025.
- FY2024 guidance narrowed: revenue $1.51B-$1.52B; adj. EPS $6.65-$6.70, at higher end of prior range.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000162828024045456/0001628280-24-045456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000162828024045456/lnth-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer